Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD38 molecule (None)
- Target
- None
- Molecular classification
- Ectoenzyme, Receptor, Type II transmembrane glycoprotein
01
Overview
CD38 is a multifunctional glycoprotein expressed on immune cells. It functions as both a receptor for CD31 and an ectoenzyme that metabolizes NAD+ and NADP+, playing roles in cell adhesion, signal transduction, calcium signaling, and immune responses. High CD38 expression is associated with poor prognosis in CLL and can contribute to resistance against PD-(L)1 immunotherapies. It is a target for monoclonal antibody therapies in multiple myeloma and other hematologic malignancies.
- Other names
- ADPRC1cADPR1
02
Mechanism of action
Anti-CD38 monoclonal antibodies bind to CD38 on tumor cells, leading to cell death through multiple mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Small molecule inhibitors target the enzymatic activity of CD38, modulating NAD+ levels and related signaling pathways.
03
Biological functions
Cell adhesionSignal transductionCalcium signalingMetabolism of NAD+Immune responseCytokine production
04
Disease associations
CancerChronic Lymphocytic Leukemia (CLL)Multiple MyelomaAutoimmune diseases
05
Safety considerations
Potential for off-target effects due to CD38 expression on normal immune cellsInfusion-related reactions with anti-CD38 monoclonal antibodiesImmunosuppression
06
Interacting drugs
Daratumumab
6 more in the full profile.
07
Biomarkers
CD38 expression level in CLL as a negative prognostic markerCD38 expression level as a predictor of resistance to PD-(L)1 immunotherapies
Beyond the preview
Go deeper on CD38 molecule (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD38 molecule (None).